CSIMarket
 
Tiziana Life Sciences Ltd  (TLSA)
Other Ticker:  
 
 
Price: $0.5153 $0.02 3.122%
Day's High: $0.5378 Week Perf: 5.16 %
Day's Low: $ 0.45 30 Day Perf: -3.23 %
Volume (M): 117 52 Wk High: $ 1.39
Volume (M$): $ 60 52 Wk Avg: $0.69
Open: $0.48 52 Wk Low: $0.45



 Market Capitalization (Millions $) 53
 Shares Outstanding (Millions) 103
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) 42
 Capital Exp. (TTM) (Millions $) 0

Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biotechnology company that focuses on the development and commercialization of innovative therapies for diseases with high unmet medical need. The company is headquartered in London, United Kingdom, with operations in the United States and Italy. Tiziana Life Sciences primarily focuses on developing treatments for cancer, autoimmune and inflammatory diseases, and COVID-19. The company's pipeline includes potential therapies based on monoclonal antibodies and small molecules to target specific disease mechanisms. Tiziana Life Sciences aims to provide patients with safe and effective treatments that can improve their quality of life.


   Company Address: Clarendon House Hamilton HM 11
   Company Phone Number: 20 7495 2379   Stock Exchange / Ticker: TLSA
   TLSA is expected to report next financial results on April 25, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Clinical and PET Scan Findings for Intranasal Foralumab: A Potential Breakthrough in Multiple Sclerosis Treatment

Published Mon, Jan 8 2024 12:00 PM UTC

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to significant disability and impairment in millions of individuals worldwide. The need for more effective and well-tolerated treatment options has prompted researchers to explore novel therapeutic approaches. In this article, we evaluate the groundbreaking findings annou...

Management Announcement

Tiziana Life Sciences' Novel Combination Therapy Signals a Promising Path to Combat Obesity-Associated Inflammation

Published Fri, Jan 5 2024 12:00 PM UTC



Tiziana Life Sciences, a leading biotechnology company, has made significant strides in their research and development efforts by filing a new patent application for a novel combination therapy. The proposed therapy combines anti-CD3 antibody (Foralumab) with a GLP-1 receptor agonist to target obesity-associated inflammation. This latest development comes at a cruc...

Clinical Study

Phase 2a Clinical Trial Launched by Tiziana Life Sciences Testing Nasal Medication in Multiple Sclerosis Patients

Published Tue, Dec 19 2023 12:00 PM UTC


Tiziana Life Sciences, a trailblazer in the development of potentially revolutionary neuro-immunomodulation treatments, has initiated dosing the first patient in its Phase 2a clinical trial exploring the effects of intranasal foralumab in patients with secondary-progressive multiple sclerosis.
In a recent announcement on December 19, 2023, the biotechnology firm det...

Clinical Study

Tiziana Life Sciences Expands Access Program for Multiple Sclerosis Treatment, Administering Foralumab to Four New Patients

Published Thu, Nov 30 2023 12:00 PM UTC


New York, November 30, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a leading biotechnology company focused on developing innovative immunomodulation therapies through novel drug delivery methods, announced today that it has successfully enrolled and dosed four additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Expanded Ac...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com